Medicare Enrolled
Dr. Jitendra Vasandani, MD
Rheumatology · Lubbock, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Vasandani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vasandani?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vasandani
Dr. Jitendra Vasandani is a rheumatology specialist in Lubbock, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Vasandani performed 174,730 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Vasandani received a total of $89,254 from 51 pharmaceutical and/or device companies across 2546 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vasandani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 5% volume in TX
$89,254 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗174,730
Medicare services
Top 5% in TX for rheumatology
Not available
Unique patients (not deduplicated)
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
101,800 | $4 | $15 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
30,360 | $10 | $39 |
| Romosozumab injection (Evenity) for osteoporosis | 20,430 | $8 | $29 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
10,550 | $33 | $119 |
| Denosumab injection (Prolia/Xgeva) | 7,860 | $19 | $59 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,375 | $93 | $270 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
827 | $55 | $189 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
575 | $119 | $364 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
446 | $97 | $345 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
153 | $123 | $415 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
80 | $6 | $21 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
79 | $21 | $110 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
74 | $8 | $40 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
57 | $10 | $64 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
27 | $48 | $181 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
22 | $48 | $270 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
15 | $58 | $184 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
23.7% high complexity
75.1% medium
1.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$89,254
Total received (2018-2024)
Avg $12,751/year across 7 years
Top 8% in TX for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
51
Companies
2,546
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$6,625
2023
$11,435
2022
$14,471
2021
$5,548
2020
$6,482
2019
$30,874
2018
$13,820
Payments by company (2024)
Amgen Inc.
$1,547
Janssen Biotech, Inc.
$1,170
UCB, Inc.
$669
ABBVIE INC.
$616
AstraZeneca Pharmaceuticals LP
$593
Novartis Pharmaceuticals Corporation
$462
GlaxoSmithKline, LLC.
$287
PFIZER INC.
$253
Radius Health, Inc.
$212
Lilly USA, LLC
$187
Mallinckrodt Hospital Products Inc.
$162
GENZYME CORPORATION
$123
ANI Pharmaceuticals, Inc.
$115
Daiichi Sankyo Inc.
$51
Boehringer Ingelheim Pharmaceuticals, Inc.
$49
Genentech USA, Inc.
$43
E.R. Squibb & Sons, L.L.C.
$31
Aurinia Pharma U.S., Inc.
$20
Alvogen Inc
$17
Sandoz Inc.
$16
Top 3 companies account for 51.1% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$23,700
E.R. Squibb & Sons, L.L.C.
$10,580
UCB, Inc.
$9,404
Amgen Inc.
$7,155
Horizon Therapeutics plc
$6,071
Regeneron Pharmaceuticals, Inc.
$5,416
Janssen Biotech, Inc.
$2,855
Cardinal Health 108, LLC
$2,320
GlaxoSmithKline, LLC.
$2,306
AbbVie Inc.
$2,057
AstraZeneca Pharmaceuticals LP
$1,979
PFIZER INC.
$1,797
ABBVIE INC.
$1,539
Genentech USA, Inc.
$1,394
Lilly USA, LLC
$1,298
GENZYME CORPORATION
$1,224
Radius Health, Inc.
$915
AbbVie, Inc.
$850
Mallinckrodt Hospital Products Inc.
$719
Celgene Corporation
$716
Horizon Pharma plc
$635
Boehringer Ingelheim Pharmaceuticals, Inc.
$590
Flexion Therapeutics, Inc.
$559
ANI Pharmaceuticals, Inc.
$442
Daiichi Sankyo Inc.
$373
Janssen Scientific Affairs, LLC
$298
Takeda Pharmaceuticals U.S.A., Inc.
$253
SANOFI-AVENTIS U.S. LLC
$216
Mallinckrodt LLC
$205
Cardinal Health 110 LLC
$200
Sandoz Inc.
$185
Antares Pharma, Inc.
$177
Pacira Therapeutics, Inc.
$127
Exeltis, USA Inc.
$109
Iroko Pharmaceuticals, LLC
$108
Merck Sharp & Dohme Corporation
$70
Bioventus LLC
$50
Ultragenyx Pharmaceutical Inc.
$45
Organon LLC
$38
Mylan Institutional Inc.
$34
Mallinckrodt Enterprises LLC
$33
Ferring Pharmaceuticals Inc.
$28
Orexigen Therapeutics, Inc.
$27
DePuy Synthes Sales Inc.
$25
ARBOR PHARMACEUTICALS, INC.
$21
Aurinia Pharma U.S., Inc.
$20
Regeneron Healthcare Solutions, Inc.
$20
Actelion Pharmaceuticals US, Inc.
$19
IDORSIA PHARMACEUTICALS US INC
$19
Alvogen Inc
$17
Purdue Pharma L.P.
$15
Top 3 companies account for 48.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Amitiza · BENLYSTA · Bimzelx · CONTRAVE · COSENTYX · CYLTEZO · Cimzia · DUEXIS · Durolane · ELIQUIS · EUFLEXXA · EVENITY · Enbrel · FORTEO · HADLIMA · HUMIRA · HYRIMOZ · Horizant · Hulio · Humira · ILARIS · INFLECTRA · INJECTAFER · KEVZARA · KEVZARA SARILUMAB INJECTION · KRYSTEXXA · LUPKYNIS · LYRICA · MONOVISC · Movantik · NUCALA · OFEV · OLUMIANT · OPSUMIT · ORENCIA · OTREXUP · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · QUVIVIQ · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · SYMPROIC · SYNVISC-ONE · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · Trintellix · Tymlos · Uloric · VIMOVO · VIVLODEX · XELJANZ · Zilretta
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Vasandani is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Vasandani experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Vasandani performed 101,800 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Vasandani receive payments from pharmaceutical companies?
Yes. Dr. Vasandani received a total of $89,254 from 51 companies across 2,546 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vasandani's costs compare to other rheumatologists in Lubbock?
Dr. Vasandani's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vasandani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Lubbock
Browse rheumatologists in Lubbock ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in TX
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in TX
Which TX rheumatologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology